HDAC8
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesHDAC8, CDLS5, HD8, HDACL1, MRXS6, RPD3, WTS, CDA07, histone deacetylase 8, KDAC8
External IDsOMIM: 300269 MGI: 1917565 HomoloGene: 41274 GeneCards: HDAC8
Orthologs
SpeciesHumanMouse
Entrez

55869

70315

Ensembl

ENSG00000147099

ENSMUSG00000067567

UniProt

Q9BY41

Q8VH37

RefSeq (mRNA)

NM_027382
NM_001313742

RefSeq (protein)

NP_001300671
NP_081658

Location (UCSC)Chr X: 72.33 – 72.57 MbChr X: 101.33 – 101.55 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Histone deacetylase 8 is an enzyme that in humans is encoded by the HDAC8 gene.[5][6][7]

Function

Histones play a critical role in transcriptional regulation, cell cycle progression, and developmental events. Histone acetylation / deacetylation alters chromosome structure and affects transcription factor access to DNA. The protein encoded by this gene belongs to class I of the histone deacetylase/acuc/apha family. It has histone deacetylase activity and represses transcription when tethered to a promoter.[7]

Histone deacetylase 8 is involved in skull morphogenesis[8] and metabolic control of the ERR-alpha / PGC1-alpha transcriptional complex.[9]

Clinical significance

HDAC8 has been linked to number of disease states notably to acute myeloid leukemia and is related to actin cytoskeleton in smooth muscle cells. siRNA targeting HDAC8 showed anticancer effects.[10] Inhibition of HDAC8 induced apoptosis has been observed in T cell lymphomas.[11] In addition the HDAC8 enzyme has been implicated in the pathogenesis of neuroblastoma.[12] Therefore, there has been interest in developing HDAC8 selective inhibitors.[13][14] At least 20 disease-causing mutations in this gene have been discovered.[15]

Interactions

See also

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000147099 - Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000067567 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. McDonell N, Ramser J, Francis F, Vinet MC, Rider S, Sudbrak R, Riesselman L, Yaspo ML, Reinhardt R, Monaco AP, Ross F, Kahn A, Kearney L, Buckle V, Chelly J (May 2000). "Characterization of a highly complex region in Xq13 and mapping of three isodicentric breakpoints associated with preleukemia". Genomics. 64 (3): 221–9. doi:10.1006/geno.2000.6128. PMID 10756090.
  6. Van den Wyngaert I, de Vries W, Kremer A, Neefs J, Verhasselt P, Luyten WH, Kass SU (Aug 2000). "Cloning and characterization of human histone deacetylase 8". FEBS Lett. 478 (1–2): 77–83. doi:10.1016/S0014-5793(00)01813-5. PMID 10922473. S2CID 12335886.
  7. 1 2 "Entrez Gene: HDAC8 histone deacetylase 8".
  8. Haberland M, Mokalled MH, Montgomery RL, Olson EN (July 2009). "Epigenetic control of skull morphogenesis by histone deacetylase 8". Genes Dev. 23 (14): 1625–30. doi:10.1101/gad.1809209. PMC 2714711. PMID 19605684.
  9. 1 2 Wilson BJ, Tremblay AM, Deblois G, Sylvain-Drolet G, Giguère V (July 2010). "An acetylation switch modulates the transcriptional activity of estrogen-related receptor alpha". Mol. Endocrinol. 24 (7): 1349–58. doi:10.1210/me.2009-0441. PMC 5417470. PMID 20484414.
  10. Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkühler C (March 2007). "HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics". Cell Res. 17 (3): 195–211. doi:10.1038/sj.cr.7310149. PMID 17325692. S2CID 30268983.
  11. Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ (May 2008). "A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas". Leukemia. 22 (5): 1026–34. doi:10.1038/leu.2008.9. PMID 18256683.
  12. Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, Kopp-Schneider A, Westermann F, Ulrich SM, von Deimling A, Fischer M, Witt O (January 2009). "Histone deacetylase 8 in neuroblastoma tumorigenesis". Clin. Cancer Res. 15 (1): 91–9. doi:10.1158/1078-0432.CCR-08-0684. PMID 19118036.
  13. Patil V, Sodji QH, Kornacki JR, Mrksich M, Oyelere AK (May 2013). "3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition". Journal of Medicinal Chemistry. 56 (9): 3492–506. doi:10.1021/jm301769u. PMC 3657749. PMID 23547652.
  14. Suzuki T, Ota Y, Ri M, Bando M, Gotoh A, Itoh Y, Tsumoto H, Tatum PR, Mizukami T, Nakagawa H, Iida S, Ueda R, Shirahige K, Miyata N (November 2012). "Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries". Journal of Medicinal Chemistry. 55 (22): 9562–75. doi:10.1021/jm300837y. PMID 23116147.
  15. Šimčíková D, Heneberg P (December 2019). "Refinement of evolutionary medicine predictions based on clinical evidence for the manifestations of Mendelian diseases". Scientific Reports. 9 (1): 18577. Bibcode:2019NatSR...918577S. doi:10.1038/s41598-019-54976-4. PMC 6901466. PMID 31819097.

Further reading

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.